. Author manuscript; available in PMC: 2023 Dec 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2022 Sep 23;10(12):3117–3123. doi: 10.1016/j.jaip.2022.09.022

Table 2.

Proton pump exposure and risk for allergic disease

Author, Year	Study Type	Exposure	Allergic Outcome and Finding
Devine, et al., 2017⁸⁰	Meta-analysis	Prenatal PPI	Asthma: HR 1.30 (95%CI:1.07–1.56)
Lai et al., 2018⁷⁹	Meta-analysis	Prenatal PPI	Asthma: RR 1.34 (95%CI 1.18–1.52)
Mitre et al., 2018⁸¹	Cohort study	PPI during infancy (age <6 months)	Asthma aHR 1.41 (95%CI: 1.31–1.52) Food Allergy aHR 2.59 (95%CI: 2.25–3.00) Allergic Rhinitis aHR 1.44 (95%CI: 1.36–1.52)
Wang et al., 2021⁸²	Cohort study	PPI during childhood (age < 18 years)	Asthma: HR 1.57 (95%CI: 1.49–1.64)
DeMuth, et al., 2013⁸³	Cross-sectional	PPI and other ASM during childhood	Food Allergy aPR 1.70 (95%CI 1.10–2.50)
Jensen et al., 2018⁸⁴	Case Control	PPI exposure during infancy	EoE aOR 6.05 (95%CI: 2.55–14.0)

ASM: acid suppressant medications, CI: confidence interval; EOE: eosinophilic esophagitis, aHR, adjusted hazard ratio, HR: hazard ratio, aOR: adjusted odds ratio, PPI: proton pump inhibitor, aPR: adjusted prevalence ratio